A reputation built on data
No pulmonary embolism interventional therapy has been studied as much as EKOS. EKOS is the only interventional device to treat PE that provides efficacy and safety data with long-term outcomes. The evidence is in the data—and in the over 90,000 patients who have benefitted from the procedure.
15
Clinical trials
1200
Patients studied
90K+
Patients treated
A decade committed to clinical advancement
-
2014
ULTIMA – Level 1 PE
data published - 2015 SEATTLE II – Pivotal PE trial published
-
2018
OPTALYSE PE – Optimized PE
protocol; long-term patient outcomes -
2021
KNOCOUT PE Registry
OPTALYSE protocol adoption & additional data collection - 2024 HI-PEITHO – First & largest of its kind in PE
Safety or efficacy is not a choice
You can have both with EKOS. See highlights and detailed data points behind some of the most critical studies in PE interventional treatment.
The OPTALYSE trial results
The SEATTLE II trial results
The ULTIMA trial results
The future of EKOS clinical evidence
With the goal of gaining a deeper understanding of intervention for treating PE, Boston Scientific continues to invest in clinical studies.
HI-PEITHO
HI-PEITHO represents the first-ever large-scale transatlantic, multi-center, prospective, randomized, controlled trial for an interventional device in pulmonary embolism (PE). It has been designed to address critical gaps in clinical evidence by comparing the clinical benefit of intervention with EKOS vs anticoagulation alone.
